Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer

Authors:

Abstract
The development of resistance is the major cause of mortality in cancer. Combination chemotherapy is used clinically to reduce the probability of evolution of resistance. A similar trend towards the use of combinations of drugs is also emerging in the application of cancer nanomedicine. However, should a combination of two drugs be delivered from a single nanoparticle or should they be delivered in two different nanoparticles for maximal efficacy? We explored these questions in the context of adaptive resistance, which emerges as a phenotypic response of cancer cells to chemotherapy. We studied the phenotypic dynamics of breast cancer cells under cytotoxic chemotherapeutic stress and analyzed the data using a phenomenological mathematical model. We demonstrate that cancer cells can develop adaptive resistance by entering into a pre-determined transitional trajectory that leads to phenocopies of inherently chemoresistant cancer cells. Disrupting this deterministic program requires a unique combination of inhibitors and cytotoxic agents. Using two such combinations, we demonstrate that a 2-in-1 nanomedicine can induce greater antitumor efficacy by ensuring that the origins of adaptive resistance are terminated by deterministic spatially-constrained delivery of both drugs to the target cells. In contrast, a combination of free-form drugs or two nanoparticles, each carrying a single payload, is less effective, arising from a stochastic distribution to cells. These findings suggest that 2-in-1 nanomedicines could emerge as a novel strategy for targeting adaptive resistance, resulting in increased anti-tumor efficacy.
Funding Information
  • National Cancer Institute (1 R01 CA135242-01A2)
  • Indo-US Science and Technology Forum
  • Congressionally Directed Medical Research Programs (BC132168, W81XWH-09-1-0700)
  • American Lung Association (LCD-259932-N)
  • American Cancer Society (122854-PF-12-226-01-CDD)